论文部分内容阅读
急性ST段抬高型心肌梗死直接经皮冠脉介入治疗时辅助应用血小板糖蛋白(GP)Ⅱb/Ⅲa受体抑制剂有助于改善梗塞相关动脉开通和心肌微循环灌注以及患者的近期及远期临床预后。不同的给药时机、剂量和途径将影响GPⅡb/Ⅲa受体抑制剂的临床疗效。冠脉内应用GPⅡb/Ⅲa受体抑制剂因提高局部血药浓度,从而更好地发挥其抗血小板聚集的作用,有望进一步改善患者临床预后。该文就冠脉内应用GPⅡb/Ⅲa受体抑制剂(尤其是替罗非班)的研究作一综述。
Acute ST-segment elevation myocardial infarction with percutaneous coronary intervention for platelet glycoprotein (GP) IIb / IIIa receptor inhibitors is helpful to improve infarct-related artery perfusion and myocardial perfusion as well as recent and far-reaching The clinical prognosis. Different timing, dosage and route of administration will affect the clinical efficacy of GP IIb / IIIa receptor inhibitors. Coronary GPⅡb / Ⅲa receptor inhibitors due to increased local blood concentration, which better play its role in anti-platelet aggregation, is expected to further improve the clinical prognosis of patients. This article reviews the study of the use of intracoronary GPIIb / IIIa receptor inhibitors (especially tirofiban).